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Introduction: Classic Bartter syndrome is a salt-wasting tubulopathy caused by mutations in the CLCNKB
(chloride channel Kb) gene. Although growth hormone deficiency has been suggested as a cause for persistent
growth failure in patients with classic Bartter syndrome, in our opinion the diagnoses of growth hormone deficiency
has been unconvincing in some reports. Moreover, Gitelman syndrome seems to have been confused with Bartter
syndrome in some cases in the literature. In the present work, we describe a new case with CLCNKB gene mutations
and review the reported cases of classic Bartter syndrome associated with growth hormone deficiency.
Case presentation: Our patient was a Japanese boy diagnosed as having classic Bartter syndrome at eight months
of age. The diagnosis of Bartter syndrome was confirmed by CLCNKB gene analysis, which revealed compound
heterozygous mutations with deletion of exons 1 to 3 (derived from his mother) and ΔL130 (derived from his
father). His medical therapy consisted of potassium (K), sodium chloride, spironolactone, and anti-inflammatory
agents; this regime was started at eight months of age. Our patient was very short (131.1cm, -4.9 standard
deviation) at 14.3 years and showed profoundly impaired growth hormone responses to pharmacological
stimulants: 0.15μg/L to insulin-induced hypoglycemia and 0.39μg/L to arginine. His growth response to growth
hormone therapy was excellent.
Conclusions: The present case strengthens the association between classic Bartter syndrome and growth hormone
deficiency. We propose that growth hormone status should be considered while treating children with classic
Bartter syndrome.
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Classic Bartter syndrome (BS), also referred to as type
III Bartter syndrome, is a rare genetic disorder char-
acterized by salt wasting from the renal tubules,
mainly the thick ascending loop of Henle [1]. It is
caused by mutations in the CLCNKB gene that en-
codes the type b kidney chloride channel (ClC-Kb).
Patients with classic BS fail to thrive from infancy and
exhibit hypokalemia, metabolic alkalosis, hyperactive
renin-aldosterone system, and overproduction of prosta-
glandins. Although potassium supplements, anti-aldos-
terone agents, and/or indomethacin are the mainstay of* Correspondence: madachi@mars.sannet.ne.jp
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reproduction in any medium, provided the ortherapy, management of growth failure and hypokalemia
is still challenging [1,2].
The association of growth hormone deficiency (GHD)
with classic BS has been anecdotally reported, and GHD
may be one of the causes of persistent growth failure
frequently observed in patients with classic BS [2-8].
However, the degrees of GHD in the reported cases have
been diverse, and hence, GHD has not yet been regarded
as a definite complication of BS. In addition, most of the
reported cases of BS accompanying GHD were not
investigated on a molecular basis [3,7,8]. Moreover,
Gitelman syndrome (GS) seems to have been confused
with BS in older reports in the literature [4-6]. Here, we
report a case of classic BS with documented CLCNKB
gene mutations in a boy who was found to have profoundLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation between classic BS and GHD.
Case presentation
Our patient was a Japanese boy born at 41 weeks of ges-
tation via spontaneous cephalic delivery, with a birth
weight of 3,680g. His family history was remarkable in
that his elder sister, who was five years older than him,
had been diagnosed as having classic BS when she was
five months old: her final height was 147.0cm (−2.1
standard deviation [SD]) and at a recent assessment her
insulin-like growth factor 1 (IGF-1) level was 286ng/mL
(normal range for her age, 168 to 459ng/mL).
At eight months of age, our patient was diagnosed as
having classic BS based on the following findings:
failure to thrive, metabolic alkalosis (pH 7.423; HCO3
-,
33.6mmol/L; base excess, +8.2), hypokalemia (2.9mEq/L),
and hyperactive renin-aldosterone system (plasma
renin activity (PRA), 270ng/mL/h; normal value for
his age, 2.58 ± 1.41ng/mL/h); aldosterone level, 850pg/mL
(2,358pmol/L; normal value for his age, 173.7 ± 96.3pg/mL).
The diagnosis of BS was confirmed by CLCNKB gene ana-
lysis, which revealed compound heterozygous mutations
with deletion of exons 1 to 3 (derived from his mother)Figure 1 Growth charts of our patient superimposed with
variations in his serum potassium levels. Black circles indicate
heights; gray circles indicate potassium levels. The arrowhead indicates
the age at which our patient could ingest potassium tablets, allowing
higher potassium levels than before. Arrow indicates the initiation of
growth hormone therapy. *Non-indomethacin anti-inflammatory
agents such as tolmetin sodium and mefenamic acid.and ΔL130 (derived from his father), the latter of which
has been reported previously by the authors TT and MA.
Medical therapy consisting of potassium (K), sodium
chloride, spironolactone, and anti-inflammatory agents
was initiated at eight months of age and is still ongoing.
However, as depicted in Figure 1, his serum K level
remained considerably low because he was unable to
consume large amounts of drugs, especially potassium
preparations. Our patient also displayed mild intellectual
impairment: he could only speak meaningful words
by the age of three, and required specialized primary
education.
When he was 11 years old, an investigation for macro-
hematuria led to the detection of renal stones with
nephrocalcinosis. This complication resolved following
the amelioration of hypokalemia, which was achieved by
our patient’s increased efforts to ingest potassium
tablets.
At 14.3 years of age, his severe short stature
(131.1cm, -4.9SD) prompted us to evaluate his growthFigure 2 Magnetic resonance imaging scan of the pituitary
gland of our patient.
Table 2 Classical Bartter syndrome with growth hormone deficiency: cases from the literature
Reference Age, years Sex Mutation GH peak (μg/L) to stimulants IGF-1 (ng/mL)
[9] 5 M IVS2-1G > C/W610X 9.3 (GLC), 8.0 (CLN), 8.2 (L-DOPA), 38.0 (ARG) Not determined
[10] 8 F Not determined 2.9 (INS), 2.0 (CLN), 6.9 (GRF) 122.1
[7] 10 M Not determined 3.20 (INS), 3.20 (L-DOPA) 25
[8] 10 F Not determined 0.70 (L-DOPA), 1.96 (CLN) 41.5
11 M Not determined 4.70 (L-DOPA), 1.79 (CLN) 39.7
11 M Not determined 0.50 (L-DOPA), 4.49 (CLN) 38.3
[2] 11 M ΔExon1-6/ΔExon1-6 7.6 (ARG) Low
14 M ΔExon1-19/ΔExon1-19 2.4 (ARG), 8.4 (GRF) Low
[3] 22 F Not determined Absence (INS), 8.0 (ARG) Not determined
Present case 14 M ΔL130/ΔExon1-3 0.15 (INS), 0.39 (ARG) 80
ARG arginine, CLN clonidine, L-DOPA L-3,4-dihydroxyphenylalanine, GH growth hormone, GLC glucagon, GRF, growth hormone releasing factor, IGF-1 insulin-like
growth factor 1, INS insulin.
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profound GHD. His serum levels of IGF-1 and IGF
binding protein 3 were 80ng/mL (normal range for
his age, 178 to 686ng/mL) and 1.92μg/mL (normal
range for his age, 2.69 to 4.16μg/mL), respectively.
Pharmacologically stimulated GH levels were 0.15 and
0.39μg/L after insulin-induced hypoglycemia and argi-
nine administration, respectively (Table 1). His bone
age was 11.4 years (Tanner-Whitehouse 2-radius, ulna
and short bones (TW2-RUS) method for Japanese individ-
uals). Magnetic resonance imaging study results revealed
no abnormalities in the hypothalamic-pituitary region
(Figure 2).
GH therapy was initiated at 14.5 years of age at a dose
of 21 to 27μg/kg/day, which restored his growth remark-
ably (Figure 1). Although his pubertal stage progressed
from Tanner stage 1 to stage 2 over the next two years,Table 3 Gitelman syndrome (including definite or probable c
Reference Age, years Sex Mutation
[12] 3 M 2614fr/unknown (SLC
9 F G186D/unknown (SLC
[5] 3 M Not determined
9 F Not determined
19 F Not determined
[6] 7 M Not determined
[11] 9 M Not determined
[13] 10 F Not determined
[14] 11 M Not determined
[15] 11 M Not determined
[4] 11 M Not determined
[16] 13 M Not determined
Cases were categorized as Gitelman syndrome according to the authors’ own judgm
ARG arginine, CLN clonidine, L-DOPA L-3,4-dihydroxyphenylalanine, GH growth horm
growth factor 1, INS insulin, PPL propranolol.his bone maturation (Δbone age/Δchronological age)
was 1.02. No significant change was observed in his
serum potassium level during GH therapy.
Discussion
To the best of our knowledge, the association of BS with
GHD was first reported in 1977 [3]. Thereafter, a
number of similar reports have been published [2-8].
However, we believe that some of the older cases
reported in the literature do not comply with the current
definition and concept of BS and thus should be recognized
as GS [4-6]. GS is another salt-losing tubulopathy caused
by mutations in the SLC12A3 gene that encodes the
thiazide-sensitive sodium-chloride cotransporter (NCCT)
[1]. Because classic BS and GS shared the laboratory find-
ing of hypokalemic alkalosis, these conditions were not
strictly discriminated until the era of molecular diagnosis.ases) and GHD: cases from the literature
GH peak (μg/L) to stimulants IGF-1
12A3) <8 (INS), <8 (ARG), <8 (CLN) Not determined
12A3) 6 (CLN) 89ng/mL
3.3 (L-DOPA), 7.3 (CLN) 0.26U/mL
9.2 (L-DOPA), 4.8 (CLN) 0.67U/mL
6.0 (CLN) Not determined
9.8 (INS + ARG) Not determined
2.1 (INS), 3.2 (CLN), 1.8 (L-DOPA) 55ng/mL
7.5 (L-DOPA), 6.9 (CLN) Normal
10.8 (GRF), 7.0 (CLN) 0.43U/mL
5 (INS), 1 (CLN), 13 (GRF) 292ng/mL
11 (CLN), 3.1 (GLC) 0.74U/mL
5.4 (INS), 5.4 (ARG), 12 (GLC-PPL) 0.19U/mL
ent, even if they were described as Bartter syndrome in the original reports.
one, GLC glucagon, GRF growth hormone releasing factor, IGF-1 insulin-like
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of classic BS.
Tables 2 and 3 summarize cases of GHD reported to
date classified as BS [2,3,7-10] and GS [4-6,11-16],
respectively. Our patient’s case is remarkable in that the
diagnosis of classic BS was established molecularly. In
addition, our patient’s GH responses to pharmacological
stimulants were most profoundly impaired among the
hitherto reported cases. Although one may argue that
hypokalemia may blunt the GH response and lead to
false negative results, the excellent response to GH
therapy made us suspicious for the presence of GHD. By
adding our patient to the existing list of cases of GHD
concomitant with BS, we believe that GHD should be
regarded as a complication in classic BS.
Flyvbjerg et al. suggested that hypokalemia is a causa-
tive factor of GHD [17]. These authors stated that mice
fed a low potassium diet showed growth retardation
with low IGF-1 levels and attenuated GH response to
GH-releasing factor (GRF). From this observation,
hypokalemia seems to be one of the possible factors
responsible for GHD in classic BS. This hypothesis is
strengthened by the findings that GHD has also been
reported in other diseases predisposing to hypokal-
emia, such as GS (Table 3) and the Bartter-like Dent
disease [18]. In addition, this hypothesis can help to
differentiate GHD (our patient in the present report)
from non-GHD (his sister). Because large amounts of
potassium could be administered via the gastric tube or
tablets, a higher serum potassium level could be maintained
in the sister, which may have prevented the development of
GHD. Furthermore, the lack of association between GHD
and antenatal BS, which is caused by mutations in either
the SLC12A1 (type I BS) or KCNJ1 (type II BS) gene, can be
explained by the observation that the correction of
hypokalemia is generally easier in antenatal BS than
in classic BS.
However, factors other than hypokalemia may be
necessary for developing GHD. Patients with familial
aldosteronism, rare genetic forms of primary aldoste-
ronism, present with hypokalemia and some of them are
refractory to medical therapy, yielding to long standing
hypokalemia [19]. Regardless, GHD has not been repor-
ted to date in patients with familial aldosteronism. Thus,
an aim of our future studies would be to determine the
precise mechanism by which GHD develops in patients
with classic BS.
Conclusions
In summary, we report our experience of profound
GHD in a boy with mutations in the CLCNKB gene, and
propose that GH status should be monitored while
treating salt-losing tubulopathies including classic BS
and GS.Consent
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